Purdue Pharma

Purdue Pharma L.P. is a privately held pharmaceutical company owned principally by descendants of Mortimer and Raymond Sackler. In 1952, the company was sold to two other medical doctors, brothers Raymond and Mortimer Sackler, who relocated the business to Yonkers, New York.

Mortimer David Sackler (December 7, 1916 – March 24, 2010) was an American-born British psychiatrist and entrepreneur who was a co-owner, with his brother Raymond, of Purdue Pharma.

Purdue Pharma L.P. is a privately held pharmaceutical company owned principally by descendants of Mortimer and Raymond Sackler. In 1952, the company was sold to two other medical doctors, brothers Raymond and Mortimer Sackler, who relocated the business to Yonkers, New York.

Raymond Sackler was, together with his brother Mortimer Sackler, owner of Purdue Pharma, the developer of OxyContin.

By 2018, eight members of the Sackler family were listed to be active or former members of the Board of Directors.

The Sackler family is an American and British family, many of whom are known for founding and owning the pharmaceutical company Purdue Pharma.

In 2007, it paid out one of the largest fines ever levied against a pharmaceutical firm for mislabeling its product OxyContin, and three executives were found guilty of criminal charges. Purdue Pharma makes pain medicines such as hydromorphone, oxycodone, fentanyl, codeine, and hydrocodone.

A July 1996 study independent of Purdue Pharma, the drug's originator, found the controlled-release formulation had a variable duration of action ranging from 10–12 hours.

Sister companies to Purdue that are also controlled by descendants of Mortimer and Raymond Sackler are Napp Pharmaceuticals in the United Kingdom and Mundipharma that are selling opioids globally.

Located in the Cambridge Science Park together with the related Napp Research Centre it is a sister company of Purdue Pharma and Mundipharma, all owned by the descendants of Mortimer Sackler and Raymond Sackler.

Purdue Pharma makes pain medicines such as hydromorphone, oxycodone, fentanyl, codeine, and hydrocodone.

In response to this and other journalism, photographer Nan Goldin launched the organization P.A.I.N., to pressure museums and other cultural institutions to divest from Sackler Family philanthropy.

P.A.I.N. (Prescription Addiction Intervention Now) is an advocacy organization founded by Nan Goldin to respond to the opioid crisis, specifically targeting the Sackler Family for manufacturing and distributing the drug Oxycontin through their corporation Purdue Pharma LP.

In response to this and other journalism, photographer Nan Goldin launched the organization P.A.I.N., to pressure museums and other cultural institutions to divest from Sackler Family philanthropy.

This led to her setting up a campaign called Prescription Addiction Intervention Now (P.A.I.N.) pursuing social media activism directed against the Sackler family for their involvement in Purdue Pharma, manufacturers of OxyContin.

Richard Stephen Sackler (born March 10, 1945) is an American billionaire businessman, and a former chairman and president of Purdue Pharma, a company purchased by his late father Raymond Sackler (best known as the developer of OxyContin), and whose connection to the opioid epidemic in the United States was the subject of multiple lawsuits and fines.

In January 2017, the city of Everett, Washington sued Purdue based on increased costs for the city from the use of oxycontin as well as Purdue not intervening when they noted odd patterns of sale of their product, per agreement in the 2007 suit noted above.

In January 2017, Everett, with a high rate of opioid abuse, sued Purdue Pharma, claiming that the company's gross negligence in the distribution of OxyContin harmed its citizens.

In May 2007, the company pleaded guilty to misleading the public about Oxycontin's risk of addiction and agreed to pay US$600 million (equivalent to approximately $M in ) in one of the largest pharmaceutical settlements in U.S. history.

Although the company shifted its focus to abuse-deterrent formulations, Purdue continued to market and sell opioids, and continued to be involved in lawsuits around the opioid epidemic in the United States.

Purdue Pharma hosted over forty promotional conferences at three select locations in the southwest and southeast of the United States.

The Sacklers' older brother, Arthur Sackler, held a one-third option in the company, which was sold to his brothers after his death.

Following Arthur's death in 1987, his option on one third of that company was sold by his estate to his brothers Mortimer and Raymond, who owned the separate company named Purdue Pharma and used Purdue Fredrick as a holding company.

Purdue Pharma L.P. is a privately held pharmaceutical company owned principally by descendants of Mortimer and Raymond Sackler.

The company that became Purdue Pharma was founded in 1892 by medical doctors John Purdue Gray and George Frederick Bingham in Manhattan as the Purdue Frederick Company.

In 1952, the company was sold to two other medical doctors, brothers Raymond and Mortimer Sackler, who relocated the business to Yonkers, New York.

Under the Sacklers, the company opened additional offices in New Jersey and Connecticut.

Under the Sacklers, the company opened additional offices in New Jersey and Connecticut.

The headquarters are in Stamford, Connecticut.

The present-day company, Purdue Pharma L.P., was incorporated in 1991, and focuses on pain management medication, calling itself a "pioneer in developing medications for reducing pain, a principal cause of human suffering".

In September 2015, the company announced it would acquire VM Pharma, thereby gaining access to worldwide development and commercial rights to an allosteric selective tropomyosin receptor kinase inhibitor program, i.e., the Phase II candidate VM-902A.

In September 2015, the company announced it would acquire VM Pharma, thereby gaining access to worldwide development and commercial rights to an allosteric selective tropomyosin receptor kinase inhibitor program, i.e., the Phase II candidate VM-902A.

In September 2015, the company announced it would acquire VM Pharma, thereby gaining access to worldwide development and commercial rights to an allosteric selective tropomyosin receptor kinase inhibitor program, i.e., the Phase II candidate VM-902A.

The company has never had an affiliation with Purdue University.

The company's manufacturing takes place at three sites: Purdue Pharmaceuticals L.P., a plant located in Wilson, North Carolina, the P.F. Laboratories, Inc. in Totowa, New Jersey, and Rhodes Technologies L.P., in Coventry, Rhode Island.